Phase 3 Readiness EB613 achieved Phase 2 endpoints; FDA-qualified quantitative BMD endpoint enables a Phase 3 registrational study, with a January 2025 target, signaling near-term licensing or co-development opportunities with large pharma seeking osteoporosis assets.

Partner Ecosystem Active collaboration with OPKO Health on obesity and metabolic programs and related partnerships; demonstrates a proven framework for co-development and future licensing across Entera's five-program pipeline.

Diverse Pipeline Five first-in-class oral peptide programs spanning osteoporosis, hypoparathyroidism, obesity, and malabsorption create cross-portfolio partnership opportunities and diversified risk for potential buyers or licensors.

Platform Differentiator N-Tab proprietary oral delivery platform differentiates Entera in the peptide space, offering potential licensing of the platform to other developers and accelerating expansion beyond Entera’s own pipeline.

High Need Markets Targeting large, unmet needs in postmenopausal osteoporosis, hypoparathyroidism, obesity, and malabsorption with potential US market access via FDA-aligned endpoints, enabling strategic partnerships and licensing discussions.